I have worked at Synageva Biopharma from its inception for fifteen years and was involved in all aspects of the company’s maturation including generation of intellectual property, fund raising, and pipeline generation. I am a primary inventor of the technologies that is the core of the Synageva’s technical advantage and includes an expansive. portfolio of expression vectors, methods and biological compounds. I had a substantial role in the raising of supportive funding, including acquisition of private investments and government grants. As the technology matured, my responsibility transitioned to pipeline development. Proteins that could have significant market opportunity and were a fit for the company’s technology were identified and inserted into the pipeline resulting in numerous compounds undergoing preclinical and clinical testing. This work culminated in a first-in-class therapy for Lysosomal Acid Lipase deficiency for which there is not currently an effective treatment. This therapy (SBC-102) is undergoing testing in affected patients.
